Literature DB >> 27272173

Clinical practice patterns for upper tract urothelial carcinoma: a nationwide survey in Japan.

Eiji Kikuchi1, Mototsugu Oya2.   

Abstract

OBJECTIVE: A comprehensive survey has not yet been conducted to investigate care patterns by urologists for the management of upper tract urothelial carcinoma.
METHODS: We conducted a nationwide survey for urologists treating upper tract urothelial carcinoma patients. The questionnaire was approved by the Japanese Urological Association and sent by mail in February 2014 to 1119 institutes in Japan. We identified 627 responders for this study.
RESULTS: Our survey demonstrated that (i) the mean number of radical nephroureterectomy cases per institution in 2013 was 7.6, (ii) the main detecting tool for upper tract urothelial carcinoma is contrast-enhanced computed tomography, (iii) the need for ureteroscopic evaluations is highly dependent on voiding urine cytology results, (iv) 67% of urologists always or often perform radical nephroureterectomy by laparoscopic surgery, (v) more than half of the urologists do not aggressively perform lymph node dissection, (vi) 75% of the urologists perform bladder cuff incision through an extravesical approach, (vii) urologists perform kidney-sparing surgery following various indications, (viii) 59% of the urologists always perform adjuvant systemic chemotherapy for high-risk upper tract urothelial carcinoma patients, (ix) the combination of gemcitabine and cisplatin is the most frequent chemo-regimen for metastatic upper tract urothelial carcinoma, and gemcitabine and cisplatin with dose reductions is also the first choice even in patients with impaired renal function and (x) 10.5% of urologists always or sometimes perform single intravesical chemotherapy immediately after radical nephroureterectomy.
CONCLUSIONS: The management strategy for upper tract urothelial carcinoma has changed with the introduction of new devices and development of instruments. The lack of clear evidence for relatively uncommon upper tract urothelial carcinoma affects the consistency of its treatment strategies.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  clinical management; nationwide survey; renal pelvic tumor; upper tract urothelial carcinoma; ureteral tumor

Mesh:

Substances:

Year:  2016        PMID: 27272173     DOI: 10.1093/jjco/hyw072

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  4 in total

1.  Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma.

Authors:  Tetsushi Murakami; Eiji Kikuchi; Hiroki Ide; Yuta Umezawa; Takayuki Takahashi; Mizuki Izawa; Kyohei Hakozaki; Keisuke Shigeta; Koichiro Ogihara; Hiroaki Kobayashi; Kunimitsu Kanai; Takahiro Maeda; Shunsuke Yoshimine; Ryuichi Mizuno; Koshiro Nishimoto; Mototsugu Oya
Journal:  BJUI Compass       Date:  2021-03-09

2.  Marital status impacts survival in patients with upper tract urothelial carcinoma: a population-based, propensity-matched study.

Authors:  Keyi Wang; Weipu Mao; Heng Shi; Guangchun Wang; Lei Yin; Jinbo Xie; Lap Hong Ian; Hui Zhang; Bo Peng
Journal:  Transl Androl Urol       Date:  2020-08

3.  Conditional Intravesical Recurrence-Free Survival Rate After Radical Nephroureterectomy With Bladder Cuff Excision for Upper Tract Urothelial Carcinoma.

Authors:  Jae Hoon Chung; Wan Song; Minyong Kang; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Hyun Hwan Sung
Journal:  Front Oncol       Date:  2021-10-07       Impact factor: 6.244

4.  Trends of incidence and prognosis of upper tract urothelial carcinoma.

Authors:  Jianping Wu; Shuqiu Chen; Xiaoli Wu; Weipu Mao; Yali Wang; Bin Xu; Donghui Zheng; Ming Chen
Journal:  Bosn J Basic Med Sci       Date:  2021-10-01       Impact factor: 3.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.